Promega Corporation

Compound Interference of CellTiter-Glo® vs PE ATPlite™ 1 Step Poster

Share

SEARCH POSTERS

Abstract

Brad Hook and Trista Schagat
Promega Corporation, 2800 Woods Hollow Road, Madison, WI USA 53711

Reducing the number of false positives in a high-throughput screen is a key goal for any researcher trying to minimize downstream efforts. Luciferase-based systems are used widely as reporters for drug screens; however, compounds in a library can inhibit luciferase, resulting in false positives. Ultra-Glo™ rLuciferase, an evolved luciferase from the firefly, Photuris pennsylvanica, is less sensitive to compound inhibition than wild-type firefly luciferase. In this study, we directly compare the abilities of the Promega CellTiter-Glo® Luminescent Cell Viability Assay, an Ultra-Glo™ rLuciferase-based luminescent ATP detection system, and the Perkin Elmer ATPlite™ 1step assay to resist common commercial luciferase inhibitors. The CellTiter-Glo® Assay has greater than 80% activity for 5 out of the 7 compounds at an inhibitor concentration of 10μM; whereas, ATPlite™ 1step has 80% activity for only 1 out of 7 compounds at the same inhibitor concentrations.

Document Icon Download the poster PDF (399kb)

  • Part# PS143
  • Printed in USA.

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.

Scientists at Your Service

Scientists at Your Service

We offer a range of services to help you succeed using Promega technologies. From product training to set up of automated systems and development of custom applications—our scientific support goes beyond the basics.

Ask us! We are here to help you.